TriSalus Life Sciences, Inc. Warrant financials
$0.8099+1.24%
Close Sep 24, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4M | $8.9M | $13.2M | $11.6M | $11.2M | $9.2M | $8.3M | $7.3M | $7.4M | $6.5M | $5.7M | $5.2M |
| Gross profit | $9.9M | $7.7M | $11.4M | $9.7M | $9.4M | $7.7M | $7.0M | $6.3M | $6.5M | $5.5M | $5.1M | $4.6M |
| Gross margin | 86.8% | 86.2% | 86.7% | 83.5% | 83.9% | 83.7% | 85.3% | 86.3% | 87.6% | 85.0% | 89.8% | 88.7% |
| Operating income | -$10.8M | -$8.4M | -$3.3M | -$9.0M | -$6.6M | -$7.3M | -$7.6M | -$8.7M | -$8.2M | -$11.7M | -$14.2M | -$18.6M |
| Net income | -$9.2M | $1.5M | -$9.8M | -$41.3M | -$9.0M | -$11.1M | -$10.9M | -$3.2M | -$5.1M | -$14.0M | -$36.4M | -$1.9M |
| Net margin | −80.5% | 17.3% | −73.9% | −356.9% | −80.3% | −120.9% | −131.8% | −43.6% | −69.7% | −216.9% | −636.9% | −36.3% |
| Diluted EPS | $-0.16 | $0.03 | $-0.21 | $-0.96 | $-0.27 | $-0.39 | $-0.39 | $-0.12 | $-0.21 | $-0.60 | $-4.67 | $-0.14 |
| EBITDA | -$10.7M | -$8.3M | -$3.1M | -$8.9M | -$6.5M | -$7.2M | -$7.4M | -$8.6M | -$8.0M | -$11.5M | -$14.0M | -$18.5M |
| Operating cash flow | -$10.1M | -$6.5M | -$2.5M | -$3.7M | -$7.3M | -$4.5M | -$5.7M | -$10.8M | -$13.4M | -$10.9M | -$9.2M | -$21.7M |
| Free cash flow | -$10.2M | -$6.6M | -$2.5M | -$3.9M | -$7.4M | -$5.3M | -$5.8M | -$11.0M | -$13.5M | -$10.9M | -$9.5M | -$21.8M |
| Diluted shares | 58.3M | 52.3M | 47.1M | 43.1M | 32.9M | 28.5M | 27.6M | 26.5M | 23.9M | 23.3M | 7.8M | 13.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $46.3M | $56.6M | $20.4M | $22.7M | $26.5M | $13.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $33.1M | $33.1M | $33.0M | $32.8M | $32.3M | $31.7M |
| Total assets | $62.4M | $71.0M | $35.3M | $36.5M | $41.3M | $28.6M |
| Total liabilities | $55.9M | $58.2M | $69.2M | $63.2M | $60.7M | $63.0M |
| Shareholders' equity | $6.5M | $12.8M | -$33.9M | -$26.7M | -$19.4M | -$34.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology